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Abstract 
Background: After the launching of the « Test & Treat » strategy and the wider accessibility to viral load (VL), evaluat‑
ing virological success (VS) would help in meeting the UNAIDS targets by 2020 in Cameroon.
Setting and methods: Cross‑sectional study conducted in the Chantal BIYA International Reference Centre for 
research on HIV/AIDS prevention and management (CIRCB), Yaoundé, Cameroon; data generated between Octo‑
ber 2016 and August 2017 amongst adults, adolescents and children at 12, 24, 36 and ≥ 48 months on ART. VS was 
defined as < 1000 copies/mL of blood plasma and controlled viremia as VL < 50 copies/mL. Data were analysed by 
SPSS; p < 0.05 considered as significant.
Results: 1946 patients (70% female) were enrolled (1800 adults, 105 adolescents, 41 children); 1841 were on NNRTI‑
based and 105 on PI‑based therapy; with 346 patients at M12, 270 at M24, 205 at M36 and 1125 at ≥ M48. The median 
(IQR) duration on was 48 months (24–48). Overall, VS was 79.4% (95% CI 77.6–81.2) and 67.1% (95% CI 64.9–69.1) had 
controlled viral replication. On NNRTI‑based, VS was 79.9% vs. 71.4% on PIs‑based, p = 0.003. By ART duration, VS was 
84.1% (M12), 85.9% (M24), 75.1% (M36) and 77.2% (≥ M48), p = 0.001. By age, VS was 75.6% (children), 53.3% (adoles‑
cents) and 81.1% (adults), p < 0.001.
Conclusions: In this sub‑population of patients receiving ART in Cameroon, about 80% might be experiencing 
VS, with declining performance at adolescence, with NNRTI‑based regimens, and as from 36 months on ART. Thus, 
improving VS may require an adapted adherence support mechanism, especially for adolescents with long‑term 
treatment in resource‑limited settings.
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Introduction
Despite many decades of continuous fight, Human 
immunodeficiency virus (HIV) is still one of the major 
global health issue, having claimed more than 35 mil-
lion lives so far, with the WHO African Region in par-
ticular being the most affected with 25.7 million people 
living with HIV in 2017 [1, 2]. As the momentum in the 
efforts to control the pandemic rises, the global com-
mitment to ending HIV/AIDS epidemic was set by the 
United Nations (UN) Assembly for 2030 [3]. Reducing 
the incidence and providing antiretroviral treatment to 
the infected people are key in the progress and achieve-
ment of this goal. A great stride in the journey towards 
ending HIV/AIDS is the ambitious treatment targets set 
by the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), the 90–90–90 strategy by 2020. This goal 
stipulates that by 2020, 90% of all people living with HIV 
will know their HIV status; 90% of all people with diag-
nosed HIV infection will receive sustained antiretroviral 
therapy; and 90% of all people receiving antiretroviral 
therapy will have viral suppression [1, 4].
Achieving these targets is especially challenging for 
developing countries where limited access to health care, 
drug availability and adequate provision of viral load 
monitoring tools and other programmatic issues need to 
be addressed. The 2017 report of the UNAIDS on end-
ing AIDS progress reveals that globally, 70% of infected 
people know their HIV status, 77% of these are receiving 
combination antiretroviral therapy (cART) and 82% of 
treated patients have virological success (VS) [4]. Studies 
conducted in some developing countries, such as Cam-
eroon reported a viral suppression level less than 80% [5–
8]. Apart from the recent Cameroon Population-based 
HIV impact assessment (CAMPHIA) [9], most of these 
studies [6, 7] were conducted before the implementation 
of the “test and treat” strategy. In addition, since most 
of the studies focused on adult populations [5, 9], data 
on viral suppression among children and adolescents in 
Cameroon are scare.
Thus, we decided to investigate on the viral suppres-
sion levels according to different age groups, therapeu-
tic regimen and duration on ART in the “test and treat” 
era which is characterized by a wider accessibility to viral 
load testing in Cameroon.
Methods
Study design and setting
This is a retrospective cross-sectional study conducted 
from October 2016 to August 2017, which corresponds 
to the effective start of “test and treat” strategy in Cam-
eroon. The study population was made up of children, 
adolescents and adults who are routinely monitored for 
viral load testing at the Chantal BIYA International Ref-
erence Centre for research on HIV/AIDS prevention and 
management (CIRCB). The CIRCB routinely receives 
and tests viral load (VL) samples mostly from 3 regions 
(the Centre, the South and the East regions of Cameroon; 
according to the allocation of HIV follow up units, to 
laboratories included in the viral load testing network 
by the Ministry of Public Health) out of the 10 existing 
regions of the country. The patients considered for this 
study were received from a total of 54 health facilities. 
However, majority of the samples were from Yaoundé, 
the city capital. Referring health facilities are district hos-
pitals (349 patients), regional hospitals/central hospitals 
(660 patients), general hospitals (601 patients), private 
hospitals (271 patients) and other types of health centres 
(65 patients). Treatment history was collected from their 
medical records.
Viral load quantification
HIV-1 RNA quantification was performed on plasma 
samples using the Abbott m2000rt RealTime HIV-plat-
form according to manufacturer recommendations 
(Abbott Molecular Inc. 1300 E. Touhy Ave. Des Plaines, 
IL 60018 200680-105; USA). A protocol using 0.6 mL of 
plasma was used for RNA extraction. The lower limit of 
detection of the assay is < 40 copies/mL of HIV-1 RNA. 
This laboratory is registered with two viral load profi-
ciency-testing programs. The study received institutional 
approvals from both National AIDS Control Committee 
(NACC) and the Chantal  BIYA International Reference 
Centre for research on HIV/AIDS prevention and man-
agement (CIRCB).
Inclusion criteria
All patients with complete information on date of sample 
collection, age, date of ART start and current ART regi-
men; together with a VL result were included. Patients 
on treatment for less than 12  months were excluded 
from our analysis. Data were queried from the data 
base and was cleaned. Age groups were defined as fol-
lows: children (0–9 years), adolescents (10–19 years) and 
adults ≥ 20 years. Virological success (VS) was defined as 
viral load (VL) < 1000 RNA-copies/mL of blood plasma, 
virological failure (VF) as VL ≥ 1000 RNA-copies/mL 
[10] and very low level viremia < 50 copies/mL [11] was 
considered as controlled viremia.
Data analysis
All data were analysed using SPSS version 20.0 (SPSS 
Inc., Chicago, Illinois), with a statistical significance 
level set at p < 0.05. Frequencies, proportions, confidence 
interval were computed and data were summarised using 
tables and figures. Hypothesis testing was performed 
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using Pearson Chi Square and Chi Square for trends as 
appropriate.
Results
Participants’ characteristics
Table  1 shows the characteristics of our study popula-
tion. A total of 1946 patients were enrolled, all reported 
to be naïve to cART at the moment of treatment initia-
tion. The majority was female (1373; 71%) were enrolled 
in this study. The median (interquartile range: IQR) age 
of our study sample was 41 years (IQR: 34–50 years); the 
median year of cART start was 2012 (IQR: 2009–2014); 
and the median duration on treatment was 48  months 
(IQR: 24–48  months). Most patients were adults 
(92.5%) and 89.3% lived in an urban area. Among the 
1841 patients on first line antiretroviral therapy, most 
patients 1017 were on tenofovir + lamivudine + efa-
virenz (TDF + 3TC + EFV) combination. Out of the 
1946 patients, 49.7% was diagnosed following a consulta-
tion, against 28.2% in voluntary screening and 15.3% of 
females during PMTCT (protection of HIV transmission 
from mother to child program).
Prevalence of viral suppression
The overall prevalence of VS after at least 12  months 
on cART at VS < 1000 copies/mL and VS < 50 copies/
mL was 79.4% (95% Confidence interval, CI 77.6–81.2) 
and 67.1% (95% CI 64.9–69.1) respectively. The median 
Table 1 Population characteristics and viral suppression levels
cART combined antiretroviral therapy, ARV antiretroviral, TDF tenofovir, 3TC lamivudine, EFV efavirenz, ATVr ritonavir boosted atazanavir, LPVr ritonavir boosted 
lopinavir, PMTCT prevention from mother to child transmission, IQR interquartile range
a Percentages in this column represent column percentage
b Percentages in this column represents row percentage
c Other first line ARV [3TC + d4T + NVP (n = 1), ABC + 3TC + EFV (n = 12), ABC + 3TC + NVP (n = 5), AZT + 3TC + EFV (n = 51), AZT + 3TC + EFV (n = 486), 
TDF + 3TC + NVP (n = 216)
d Lopinavir based (n = 31) and atazanavir based (n = 68). * p-value for virological success at < 1000 copies/mL
Variable Overalla
N = 1946
< 50 copies/mLb
N = 1305 (67.1%)
< 1000 copies/mLb
N = 1546 (79.4%)
≥ 1000 copies/mLb
N = 400 (20.6%)
p-value*
Age in year, median (IQR) 41 (34–50) 41 (34–50) 42 (34–50) 39 (33–49) < 0.001
Year of cART start, median (IQR) 2012 (2009–2014) 2012 (2009–2014) 2012 (2009–2014) 2011 (2008–2013) < 0.001
Duration on cART in month, median (IQR) 48 (24–48) 48 (24–48) 48 (24–48) 48 (36–48) 0.001
Gender, n (%)
 Male 573 (29.4) 352 (61.4) 435 (75.9) 138 (24.1) 0.013
 Female 1373 (70.6) 953 (69.4) 1111 (80.9) 262 (19.1)
Age groups, n (%)
 Children 41 (2.1) 25 (61.0) 31 (75.6) 10 (24.4)
 Adolescents 105 (5.4) 46 (43.8) 56 (53.3) 49 (46.7) < 0.001
 Adults 1800 (92.5) 1234 (68.6) 1459 (81.1) 341 (18.9)
Therapeutic regimen, n (%)
 First line 1841 (94.6) 1261 (68.5) 1471 (79.9) 370 (20.1) 0.037
 Second line 105 (5.4) 44 (41.9) 75 (71.4) 30 (28.6)
ARV combination, n (%)
 TDF + 3TC + EFV 1070 (55.0) 770 (72.0) 890 (83.2) 180 (16.8) < 0.001
 Other 1st line  ARVc 771 (39.6) 491 (63.7) 581 (75.4) 190 (24.6)
 ATVr or LPVr  Based  ARVd 105 (5.4) 44 (41.9) 75 (71.4) 30 (28.6)
Circumstance of diagnosis, n (%)
 Consultation 967 (49.7) 625 (64.6) 750 (77.6) 217 (22.4) < 0.001
 Voluntary 549 (28.2) 396 (72.1) 461 (84.0) 88 (16.0)
 PMTCT 210 (10.8) 153 (72.9) 180 (85.7) 30 (14.3)
 At birth 41 (2.1) 22 (53.7) 25 (61.0) 16 (39.0)
 Other/unknown 179 (9.2) 109 (60.9) 130 (72.6) 49 (27.4)
Urban vs rural, n (%)
 Urban 1737 (89.3) 1171 (67.4) 1388 (79.9) 349 (20.1) 0.004
 Rural 144 (7.4) 98 (68.1) 117 (81.2) 27 (18.8)
 Unknown 65 (3.3) 36 (55.4) 41 (63.1) 24 (36.9)
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age, median year of cART initiation, and median dura-
tion on cART for patients failing treatment vs. those on 
VS at ≥ 12 months of cART were: 39 [IQR: 33–49] years 
vs. 41 [IQR: 34–50] years, p < 0.001; calendar year 2011 
[IQR: 2008–2013] vs. calendar year 2012 [IQR: 2009–
2014], p < 0.001; and 48 [IQR: 36–48] months vs. 48 [IQR: 
24–48] months, p = 0.001; respectively.
According to ART duration, VS was 84.1% at 
12  months (M12), 85.9% at 24  months (M24), 75.1% at 
36 months (M36) and 77.2% at more 48 months (≥ M48), 
p = 0.001. The overall VS was 75.9% (95% CI 72.3–79.2) 
for males and 80.9% (95% CI 78.8–82.9) for females, 
p = 0.013; while overall controlled viremia was 61.4% 
for male and 69.4% for female (p = 0.001). There was 
a large variation of VS prevalence with respect to age 
groups for both VS thresholds (p < 0.001); with the high-
est prevalence of virological failure at VS ≥ 1000 copies/
mL being recorded among adolescents (46.7%), followed 
by children (24.4%). When compared according to cART 
regimens, TDF + 3TC + EFV, others first line combina-
tions, and ritonavir-boosted lopinavir (LPV/r)/atazanavir 
(ATV/r)-based ARV) at VS < 1000 copies/mL, patients on 
TDF + 3TC + EFV recorded the highest VS (83.2%) ver-
sus 71.4% on PI/r-based regimens, p < 0.001.
According to circumstances of HIV diagnosis, at both 
VS < 50 copies/mL and VS < 1000 copies/mL, those diag-
nosed during PMTCT had the highest prevalence (72.9% 
and 85.7% respectively), followed by patients screened 
voluntarily (72.1% and 84.0% respectively); with patients 
diagnosed at birth recording the worst performance 
(53.7% and 61.0% respectively); p < 0.001. Figure 1 shows 
that for VS < 1000 copies/mL per duration on cART and 
per gender, the prevalence ranged from 69% to 80% (at 36 
and 24 months respectively) for male (p = 0.625); against 
78% to 89% (≥ 36  months and 24  months respectively) 
for female (p < 0.001). On the other hand, Fig.  2 shows 
that for the same VS level per duration on cART and per 
1st line NNRTI (non-nucleoside reverse transcriptase 
inhibitor)-based therapy, it ranged from 76% to 87% (at 
M36 and M24 respectively), p = 0.001).
Discussion
In this study, we aimed at estimating the prevalence of 
virological success per age groups, duration on cART 
and therapeutic line among HIV/AIDS patients in Cam-
eroon. It shows that at the start of the “test and treat” era 
in Cameroon, the overall prevalence of VS < 1000 copies/
mL after at least 12 months of cART was 79.4% (95% CI 
77.6–81.2); about 11% away from the 90% target set by 
UNAIDS by 2020. This performance is less than the 82% 
reported global VS performance [4]. In the other hand, 
the prevalence of patients with controlled viremia after 
at least 12  months of cART was 67.1% (95% CI 64.9–
69.1), far away from the high VS reported in many west-
ern countries [12]. The virological failure rate of 20.6% 
observed in this study was within the range reported in 
other developing countries, which is 3.7% to 26.0% [7]. 
Previous studies in Cameroon reported VS between 
72.1 and 90.2% [5, 6, 9, 13], with the differences in VS 
Fig. 1 On‑treatment virological success per duration on cART and 
per gender. cART combination antiretroviral therapy, VL viral load, F 
female, M male. *p‑value for trend of virological success per duration 
on cART and per female gender; **p‑value for trend of virological 
success per duration on cART and per male gender; ***overall p‑value 
for trend of total population. Error bars represent 95% confidence 
interval
Fig. 2 On‑treatment virological success per duration on 1st 
line‑NNRTI‑based cART. cART combination antiretroviral therapy, VL 
viral load, 1st line first line therapy‑NNRTI‑based. *p‑value for trend 
of the 1st line over time. Error bars represent the 95% confidence 
interval
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performance mostly attributed to differences in study 
population characteristics and duration on cART. Our 
result is closely similar to the recent and country wide 
population based HIV impact assessment (CAMPHIA) 
study which found 80% VS. The high VF in this study 
may be either related to the fact that many patients might 
be treatment failure suspects and/or repeat testers after 
suspect failure, which are known to record a high VF 
compared to patients on routine monitoring [14]; or to a 
relatively higher proportion of children and adolescents 
(compared to other studies in Cameroon), who generally 
have a low response [9, 14–19], especially in settings with 
a weak health system.
The median age (IQR) of virally suppressed patients 
was 42 years (34–50 years) versus 39 years (33–49 years) 
in treatment failure patients (p < 0.001). In fact, our result 
shows that children (< 10 years) and/or adolescents (10–
19 years) are much less likely to achieve virological suc-
cess compared to adult populations (p < 0.001). Poor ART 
response of HIV-infected children (especially infants 
perinatally infected) compared to adult populations is 
well documented. This could be justified by the higher 
viral replication and the less efficient immune response 
against infections in infants [20–22]. Moreover, patients 
with pre-therapy viral load of > 500,000 copies/mL (com-
monly observed in children) are known to have longer 
time to VS and a higher probability of virological rebound 
after VS [23]. Nonetheless, suboptimal adherence level is 
also a major challenge often reported in children [24].
The lack of adherence and adequate provision of psy-
chological supports in children and adolescents has been 
reported to represent the major cause of loss to follow-
up and virological failure [14, 24]. The VS performance 
observed in our study in adolescent population in par-
ticular is a call for concern. It was also recognized in 
some settings that they have a limited access to antiret-
rovirals (ARVs) [3]. Thus, there is a need to give a special 
considerations to these vulnerable groups in the provi-
sion of health care delivery. In addition, they should have 
more access to drug resistance testing because they have 
been reported to record generally a high burden of HIV 
drug resistance [25, 26].
According to gender, females are more likely to expe-
rience virological success than men 80.9% vs 75.9% 
respectively, p = 0.013). Even though the recent CAM-
PHIA study reported a relatively higher VS in men than 
women (80.1% vs 79.2%) [9], data from many studies sug-
gest that men are likely to experience virological failure 
than females [4, 15]. This can be justified by their high 
risk related behavioural patterns. For example, studies 
reported that the masculine gender norms contribute to 
greater risk-taking; expressing manhood by having mul-
tiple sex partners, refusal to use condoms, alcohol and 
substances abuse; and poorer uptake of health services 
[27–30]; all leading to a poorer adherence and treat-
ment interruption which favour treatment failure. In 
addition, it is recognised especially in some Sub-Saharan 
Africa that men are most likely to die of HIV/AIDS than 
women [27, 30] because they have lower knowledge of 
HIV/AIDS [16], and present generally to health service 
latter with advanced disease conditions [30–32]. While 
sustaining and improving the access to ARV and VS in 
women through existing programs, men should not be 
left behind. Since current health system design may be 
responsible for these gaps, designing interventions sepa-
rately for males and females, filling the gaps in the contin-
uum of HIV/AIDS care [33] and increasing case finding 
through PMTCT, index and work place testing [4, 28, 30] 
may help achieve the 90% target UNAIDS goal.
The treatment failure rate at VS < 1000 copies/
mL was higher among patients on second line com-
pared to first line patients (28.6% vs 20.1% respectively, 
p = 0.037). When compared according to ARV combi-
nations (TDF + 3TC + EFV, others first line combina-
tions or protease inhibitors-based ARV, patients on 
TDF + 3TC + EFV recorded the highest virological suc-
cess (83.2%) versus 75.4% and 71.4% for other first line 
and PI-based regimen respectively (p < 0.001). Most stud-
ies reported more than 80% VS in patients on PI based 
therapy [34–36]. Even though low rate of switching 
from first to second line, which may affect second line 
response is sometimes reported [37], Protease inhibitors 
(PIs) based regimens are generally protective against VF 
[19]. The small number of patients (105) on second line 
in our study may not be representative; however, this may 
indicate adherence challenges among patients in second 
line treatment. Our result also suggests that there is a 
better response to TDF + 3TC + EFV combination com-
pared to other first line options (including those that are 
nevirapine (NVP)-based and those containing zidovudine 
(AZT), stavudine (d4T) and abacavir (ABC) as NRTI-
backbone). In fact, this combination has been found to 
be equivalent or superior to its comparator arms (other 
nucleoside reverse transcriptase (NRTI)—backbone and/
or NNRTI) in many studies [38–41].
According to duration on therapy, VF was associ-
ated with longer stay on cART (median year of cART 
start: 2011 (2008–2013) versus 2012 (2009–2014 for VF 
and VS group respectively, p < 0.001). Similar trend was 
equally reported after 6 months and 48 months on cART 
in a review [8]. The individual increase in the lack of tol-
erability and the emergence of multi strain viruses with 
time greatly account for this reduced VS [6, 14, 42, 43]. 
A study in Cameroon reported that the prevalence of VF 
and resistance increased with time on ART, from 12.0 to 
8.0% in the 6- to 12-month group to 31.3% and 27.1% in 
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the > 72-month group, respectively [5]. Unavailability of 
ART at the treatment centre was reported as the single 
most common cause for incomplete adherence in rural 
Cameroon [44]; strategies to improve adherence through 
health system strengthening should be implemented. 
To limit the emergence of viral resistance and achieved 
a higher and sustained VS, the use of novel drug classes 
such integrase strand transfer inhibitors (INSTI) class in 
first line, which has a demonstrated excellent efficacy and 
resistance profile in clinical practice, and recommended 
by many guidelines today will be a good option [43, 45–
48]. Figure 1 suggests that the variation of VS over time 
in females showed a significant level (p < 0.001), while 
variation in males was not significant (p = 0.625). Gen-
der differences in HIV disease progression and treatment 
outcomes among females and males [49] as well as other 
socio cultural characteristics, behavioural differences and 
disease perception may account for such differences.
According to reasons/circumstances of diagnosis, the 
VS varied significantly among the patients (p < 0.001). 
The VF among patients diagnosed during consultation 
was 22.4%, against 16.0% in patients who undertook vol-
untarily testing and 14.3% in women diagnosed during 
PMTCT. Additional data should be collected to better 
understand how engaging potentially infected persons 
and key populations in voluntary screening may con-
tribute in achieving also the third “90”. Contrary to other 
studies, we noted a higher VS among patients from Rural 
area compared to those in urban area (p = 0.004). The 
major limitation of this study is that data were not col-
lected on whether VL was requested for routine moni-
toring, suspects failure or repeat testers after failure, and 
might have confounded our estimates. Additionally, even 
though the acquired HIV drug resistance among patients 
failing ART is still of concern in Cameroon, we could not 
present these data in our study because they were not 
performed. We therefore recommend subsequent studies 
to investigate other predictors to VF and acquired HIV 
drug resistance profile among patients failing ART in 
such setting.
Conclusion
In this sub-population of patients receiving ART in 
Cameroon, about 8 out of 10 might be experiencing 
VS (with a gap of 10% below the required target set 
by 2020), with poorer outcomes among adolescents 
and those as from 36  months on cART. Furthermore, 
VS appears higher in females and in those treated with 
TDF + 3TC + EFV compared to other NNRTI-based or 
PI/r-based regimens. Thus, strategies towards improved 
monitoring of adolescents, male and long-term treated 
patients are crucial in maximising VS, while access to 
timely switch of ART and/or drug resistance would 
help in alleviating the burden VF and in meeting the 
target for ART response in RLS.
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